HDAC9 and liver disorder: Notably, very few HDAC inhibitors have completed phase II testing due to adverse side effects including fatigue, constipation, diarrhea, and dehydration.59 Ideally, combined GWAS and EWAS information will arm clinicians and dieticians with the tools to design evidence-based lifestyle modification strategies tailored to prevent liver disease developing in at-risk individuals and from passing on unhealthy epigenetic traits to future generations.